NAS10028,945+0.02%S&P7,552−0.45%GOLD$4,296−0.86%BTC$75,632+0.03%VIX17.71+2.97%live tape · as of 23:00 UTC · 16 Sep
The Screen · Healthcare · Drug Manufacturers - General
Gilead Sciences
GILD · a US exchange · USD · Market cap $181.8B · 17,000 employees
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
FAIL · Does not pass the screen
146.64 USD
At the last full screen 2026-09-08
Screened 2026-09-08 · the tape above runs as of 23:00 UTC · 16 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Gilead Sciences holds its Markup at $146.64. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-09-08
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$146.64
Valuation
N/A trailing · 14.83 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.35
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
42.25%
Below 33%
Interest-bearing debt is 42.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
5.04%
Below 33%
Cash held in interest-bearing accounts and securities is 5.0% of assets, under the one-third limit.
Pass
Receivables
21.14%
Below 49%
Money owed to the company is 21.1% of assets, under the 49% limit.
Pass
Revenue purity
1.19%
Below 5%
Only 1.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 6% discount to our $154.85 fair value, strong competitive moat, 10.20% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 5.6% margin of safety to the base estimate.
Third-party analyst targets: 27 covering, consensus Buy. The average target sits +9% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Unethical Debt Woes for Gilead's Valuation
Imagine a pharmaceutical lab in the heart of the US, working on life-saving treatments, a beacon of hope for countless patients. That's Gilead Sciences, with a strong moat in its industry and a promising 10% revenue growth. But for all its medical prowess, the company is weighed down by a significant debt ratio that fails our ethical screen. This is why we're steering clear.
Gilead's market price of $143.44 sits comfortably under our fair value estimate of $154.88, suggesting an 8% margin of safety. The company boasts a strong moat and a consensus buy rating from 27 analysts, with a median target price of $160. Despite this, the profit margin is deeply in the red at -11%, and the Return on Equity (ROE) is -21%, painting a picture of financial distress.
Risks are glaringly obvious here, with the ethical failings around debt being a central concern. Coupled with the profit and ROE figures, it's clear that Gilead's financial health is compromised. While the valuation might look tempting, the underlying ethical and financial issues劝 us to stay on the sidelines. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GILD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (27 analysts) rates it buy, with a mean price target of $157.
2026-08-06Markup$131.76+1.9%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-05Markup · changed$129.31+0.0%Entry 10
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-04Distribution$129.31+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-03Distribution$129.31+0.0%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-02Distribution$129.31+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-01Distribution$129.31+0.0%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-31Distribution$129.31+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Accumulation$129.16+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (29 analysts) rates it buy, with a mean price target of $158.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
